ArticleSchizophrenia (Heidelberg, Germany)2026
East Asian herbal medicine as an adjunctive treatment for schizophrenia: a systematic review and meta-analysis.
Article in Schizophrenia (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundHerbal medicine is widely used as an adjunctive treatment for schizophrenia, but evidence remains limited.
aimsTo evaluate the effectiveness and safety of East Asian herbal medicine combined with antipsychotics in schizophrenia spectrum disorders.
methodsTen sources including MEDLINE, EMBASE and CENTRAL were searched up to January 2025 for randomised controlled trials comparing East Asian herbal medicine combined with antipsychotics versus antipsychotics alone. Primary outcome was the overall symptom scores (PANSS/BPRS). Secondary outcomes included adverse events, negative and positive symptom scores, response rates, social function, quality of life, recurrence, and adherence. Risk of bias was assessed using the Cochrane RoB 2, and evidence certainty using GRADE.
results270 studies comprising 26,053 participants were included. East Asian herbal medicine combined with standard-dose antipsychotics improved overall symptom (SMD - 1.38, 95% CI - 1.60 to -1.17; 181 studies, 18,569 participants; low-certainty evidence) and reduced adverse events (RR 0.56, 95% CI 0.51-0.62; 92 studies, 8983 participants; low-certainty evidence) versus antipsychotics alone. East Asian herbal medicine combined with low-dose antipsychotics versus standard-dose antipsychotics showed symptom improvement (SMD - 0.92, 95% CI - 1.54- - 0.29; 25 studies, 1907 participants; low-certainty evidence) and fewer adverse events (RR 0.44, 95% CI 0.34-0.58; 6 studies, 450 participants; low-certainty evidence).
conclusionLow-certainty evidence suggests that East Asian herbal medicine as an adjunct to antipsychotics may improve symptoms and reduce adverse events in schizophrenia. However, most studies raised concerns regarding the risk of bias, and potential publication bias was suspected. Results require cautious interpretation and further high-quality studies are needed.
Identifiers
42426034What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.